Brinzolamide

證據等級: L5

預測適應症: 1 個

Brinzolamide: From Open-angle Glaucoma / Ocular Hypertension to Primary Hereditary Glaucoma

One-Sentence Summary

Brinzolamide is a topical carbonic anhydrase inhibitor (CAI), used clinically to lower elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma (PHG), a developmental form of glaucoma driven by structurally impaired aqueous humor outflow. Currently, no clinical trials and no publications specifically supporting this combination have been identified — this prediction is mechanism-driven and sits at the hypothesis stage.

Quick Overview

Item	Content
Original Indication	No Taiwan registration found; pharmacologically established for elevated IOP in open-angle glaucoma / ocular hypertension
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.48%
Evidence Level	L4 (mechanism-based model prediction; no clinical trials or publications found)
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Brinzolamide is a selective inhibitor of carbonic anhydrase II (CA-II) in the ciliary body epithelium. By blocking CA-II, it suppresses bicarbonate synthesis — the rate-limiting step for aqueous humor secretion — and thereby reduces IOP. This mechanism is pharmacologically well-established and shared with the broader CAI drug class (e.g., Dorzolamide, Acetazolamide).

Primary Hereditary Glaucoma (PHG), also called Primary Congenital Glaucoma (PCG), is caused by developmental malformation of the trabecular meshwork, most commonly due to CYP1B1 mutations. The structural defect impairs aqueous humor drainage, causing chronic IOP elevation and progressive optic nerve injury. The mechanistic logic for repurposing is direct and complementary: PHG's pathology lies in the outflow pathway, while Brinzolamide targets the inflow side — reducing the volume of aqueous humor that needs to drain. Even when outflow resistance is fixed by an irreversible structural defect, suppressing production can still meaningfully lower IOP and protect the optic nerve.

Class-effect precedent supports biological plausibility. Dorzolamide, a close structural analogue in the same CAI class, is already used as adjunctive or bridge therapy in pediatric congenital glaucoma when surgical correction is delayed or incomplete. TxGNN's high score of 0.9948 reflects this mechanistic alignment rather than evidence from clinical studies, which are absent for this specific drug–disease combination.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The scientific case for Brinzolamide in Primary Hereditary Glaucoma is mechanistically coherent — the drug directly suppresses aqueous humor production, offering a complementary approach to the outflow obstruction that defines this condition. However, with zero clinical trials and zero published literature specifically supporting this combination, the evidence is at L4 (model prediction + mechanism only), which is insufficient to advance without foundational corroborating data.

To proceed, the following is needed:

Systematic review of the CAI class (especially Dorzolamide) in congenital and hereditary glaucoma to formally establish class-effect precedent
Preclinical evidence in animal models of CYP1B1-mutant glaucoma to quantify IOP-lowering magnitude and durability
Retrospective case series or registry data on Brinzolamide use in pediatric or congenital glaucoma patients
Paediatric pharmacokinetic and safety assessment: systemic CA-II inhibition risk, ocular surface tolerability, and long-term IOP trajectory in the developing eye
Regulatory pathway scoping with Taiwan TFDA for orphan/paediatric ophthalmic drug development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.